Blue Matter Blog

Blue Matter Breakfast Club Meeting #3 – A Discussion with Theresa Heggie of Alnylam Pharmaceuticals
November 8, 2019

The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The third Breakfast Club meeting was on 5th November 2019 at Skylounge restaurant in Zug, Switzerland.  …

A Framework for Successfully Launching & Commercializing Rare Disease Products
January 28, 2019

Regardless of the product, launching a new biopharmaceutical drug is a time-consuming, expensive, and complex undertaking.  It requires sound strategy, expert planning, and effective cross-functional coordination to get everything done right.  The analogy is certainly not new but launch really is akin to conducting a symphony orchestra, ensuring that all members play their parts correctly, …

Dealing with the Constant State of Launch in Oncology
November 7, 2018

Part Two in a Six-Part Series on Oncology Product Commercialization In Part One, we mentioned that the launch frequency for oncology products has increased significantly over the last several years.  While this trend is seen in other therapeutic areas across the industry, we believe the combination of factors driving this in oncology are somewhat unique …